• trong execution since going public on the Canadian Securities Exchange (the “CSE”) in January 2023
• Atlas launches D*gg Lbs brand in collaboration with Snoop Dogg, first SKUs ready for OCS summer product call
• Solidifying integrated value chain with Canadian cultivation facilities and Israeli acquisitions
• Streamlining operations and leveraging existing value chain capabilities
• Atlas will host an investor webinar on June 22 at 8 AM PT/ 11 AM ET

CHATHAM, ONTARIO and TEL-AVIV, ISRAEL, June 07, 2023 (GLOBE NEWSWIRE) — Atlas Global Brands Inc. (“Atlas Global”, “Atlas” or the “Company”) (CSE: ATL), a cannabis company with expertise across the value chain, is pleased to provide an update on the Company’s recent milestones, business integration activities and global growth catalysts. Atlas will also host a webinar on June 22, 2023, to provide an overview of the Company and its strategic objectives ahead. Investors can register to attend here. A recording of the webinar will be made available on Atlas’ investor relations website.

Sales, Marketing and International Shipments

For the summer 2023 product call with the Ontario Cannabis Store (“OCS”) Atlas is excited to launch new products under its D*gg Lbs brand, in collaboration with Snoop Dogg. The Company entered into an exclusive licensing agreement with Snoop Dogg in March 2023 to launch new brands globally in legalized cannabis markets. All D*gg Lbs products are curated by Snoop Dogg himself, with the aim to deliver premium products in all cannabis categories. Atlas will launch the following products this summer through the OCS:

• Lodi Dodi OG 3.5g flower
• Cryptic Chronic 3.5g flower
• Cryptic Blueberry 1g Distillate Infused Blunt
• Juicy OooWee 2 x 0.5g Distillate Infused Pre-rolls
• Lodi Dodi OG 1g Blunt
• Cryptic Chronic 2 x 0.5g Blunts
• Cryptic Blueberry AIO 1g Vape
• Juicy OooWee AIO 1g Vape

Atlas expects to deliver its first shipment of D*gg Lbs products to Israel from its facility in Chatham, Ontario in late June 2023, shipping three new flower SKUs. The shipment to Israel will also include Atlas’ Vertical flower brand, for a total expected shipment of close to 400 kg in product.

Vertical Integration in Israel

Atlas has a strong foothold in Israel with controlling interests in 3 pharmacies and definitive agreements to acquire controlling interests in 6 additional pharmacies in core markets in Israel, which combined will be a total of 9 pharmacies. The acquisitions of the pharmacies are expected to close subject to receipt of all necessary approvals and the satisfaction of all other customary conditions to closing. Additionally, Atlas has a definitive agreement to acquire an Israeli Trading House, located in Tel Aviv, which will be leveraged as an export distributor. Atlas intends to utilize its Trading House to hold an inventory of quality products which will be sold to all Israel-based pharmacies in the country to bring patient focused products to market. For efficiency and costs savings, the Trading House will supply Atlas’ pharmacies in Israel, strengthening Atlas’ globally owned supply chain.

Business Integration Activities

Since going public five months ago through reverse takeover of two Canadian cannabis companies and the acquisition of four Israel-based companies, Atlas’ management team prioritized streamlining operations to align with the Company’s overall international growth strategy and to enhance cost efficiency. As part of these efforts, all packaging activities have been relocated to the Company’s facility in Chatham, Ontario, enabling centralized manufacturing and maximizing production capabilities. Atlas’ facility in Chatham, Ontario now serves as the Canadian hub for the processing of domestic and EU GMP flower and oils for international markets.

Atlas completed the acquisition of GreenSeal Cannabis Company, Ltd. and GreenSeal Nursery Ltd. on April 28, 2023, a GACP & CUMCS certified indoor grow facility located in Stratford, Ontario. This facility produces 3,500 kg of flower for the domestic and international markets and will expand Atlas’ genetic pipeline for new flower cultivars and shape product innovation through its nursey program.

In close proximity to Atlas’ EU-GMP facility in Chatham, Ontario, GreenSeal will help Atlas meet the growing demand for high-quality flower in key markets such as Israel, Australia, Germany, and others.

Atlas’ two Ontario facilities increase national distribution with 18 new SKUs entered into the OCS and other provincial markets as listings permit during the Company’s fiscal 2024 year.

Key Areas of Focus

As part of its business integration strategy, Atlas will maintain its focus on streamlining operations, international growth and strengthening its balance sheet. Atlas’ go-forward business strategy is as follows:

1. International growth by leveraging its EU-GMP certified facility in Chatham, Ontario and GACP & CUMCS certified facility in Stratford, Ontario for export.
2. Integrated value chain expansion in Israel through the acquisition of a Trading House and pharmacies to expand its vast assortment of quality demanded products for medical cannabis patients.
3. Streamline Canadian operations to support global scale-up. Utilization of two facilities in Ontario to build brands and develop innovation to scale exports of flower and other categories into international medical markets.

“The unveiling of these summer product launches – domestically and globally – marks a pivotal moment for our team and our shareholders, especially in collaboration with Snoop Dogg. Our vision is to establish Atlas as a leader in the global cannabis industry. Within a short timeframe, we have pursued five strategic acquisitions, one of which has already been successfully finalized while the others await regulatory approvals. We firmly believe these strategic initiatives will yield significant value for Atlas’ shareholders,” said Bernie Yeung, CEO of Atlas Global.

Investor Webinar

On June 22, 2023, Atlas’ CEO Bernie Yeung and CFO, Jason Cervi will host a webinar to provide an investor update at 8 AM PT/ 11 AM ET. Register here.

Management Change

Effective June 2, 2023, Jeff Gossain, Chief Operating Officer, is no longer engaged with the Company.

About Atlas Global Brands

Atlas Global is a global cannabis company operating in Canada and Israel with expertise across the cannabis value chain, including cultivation, manufacturing, marketing, distribution, and pharmacy. Atlas currently distributes to eight countries: Australia, Canada, Denmark, Germany, Israel, Norway, Spain, and the United Kingdom. In addition to a differentiated product mix, Atlas operates two licensed cannabis facilities – one with EU-GMP, has a majority interest in 3 medical pharmacies in Israel and has entered into binding agreements for the acquisition of a majority interest in a Trading House and 6 additional medical cannabis pharmacies in Israel.

Learn more by visiting: www.atlasglobalbrands.com

Contacts

Bernie Yeung
Chief Executive Officer
1-844-415-6961
invest@atlasglobalbrands.com

Alyssa Barry
Media and Investor Relations
1-833-947-5227
invest@atlasglobalbrands.com

Forward-Looking Information

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements.

Forward-looking information in this news release is based upon assumptions that are subject to significant risks and uncertainties, including assumptions that (or regarding): the contemplated product launches will proceed as planned and on the expected timeline; there will be no material interruptions in the production, shipment or distribution of Atlas’ products; that all inputs into the Atlas’ products will be available on a timely basis; all licenses and regulatory approvals can be obtained for shipments of (or in respect of) Atlas Global’s products in a timely manner; there is sustainable demand for Atlas Global’s products in the domestic and international markets in which it distributes its products; Atlas will benefit from synergies related to its acquisitions; the pending acquisitions will proceed as contemplated, and the transactions contemplated thereby will be completed in accordance with their terms; the general regulatory environment in which the Company operates; foreign exchange rates; financial, market and political conditions impacting the industry and markets in which the Company operates; the impact of competition on the Company’s overall growth strategy.

The forward-looking information reflects management’s current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking information, including that: product launches could be delayed by any number of factors, including, but not limited to, supply chain disruptions, delays in production, product recalls, shipping delays, unfavourable market conditions, Atlas’ inability to obtain required regulatory approvals and economic, financial and political events or instability; Atlas’ production capacity may be materially less than expected; the financial, market, regulatory and political environment in which Atlas operates could change in a way that negatively affects Atlas’ operations; Atlas’ completed acquisitions will not be accretive to Atlas’ overall growth strategy; one or more conditions to complete by the pending acquisition will not be satisfied and one or more of the pending acquisitions could be terminated.

Although the Company believes that the assumptions and factors used in preparing the forward-looking information are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking information.

The forward‐looking statements set forth herein concerning the Company reflect management’s expectations as at the date of this news release and are subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise, other than as required by law.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

• • In late 2021, Software Effective Solutions Corp. dba MedCana acquired five companies with licenses to produce, process, and export cannabis with and without T.H.C. The purchased companies have a combined total area of 105 Acres (42.84 Hectares). MedCana has also secured the option to expand operations to an additional 177 Acres (72 Hectares) as needed.
  • The primary area of operation is outside of Marinilla, a small town approximately one hour away from Medellin in the department of Antioquia, Colombia. Initial design as well as all environmental, geological, and hydrological have been completed and the project will be ready to break ground in June of 2023.
  • In September 2022, MedCana also acquired Tokan Corp’s assets, a software company, with the focus of creating an ERP platform for the cannabis industry to track the seed to patient process.
  • In October of 2022, MedCana acquired Eko2O S.A.S. a company focused on design and distribution of greenhouses and advanced irrigation platforms. The track record, experience, and industry knowledge that CEO Juan Ricardo Velez brings has set the company up for explosive growth in the region while also dramatically decreasing costs for MedCana’s subsidiaries in the region.

SFWJ CEO Gabriel Diaz states, “We are extremely pleased with the progress we’ve made in the past several months. We look forward to updating shareholders, and are committed to doing everything possible to increase shareholder value.”

ABOUT SFWJ: 

Software Effective Solutions/MedCana is a global infrastructure and holding company in the cannabis industry. Currently, MedCana has five companies focused on pharmaceutical cannabis production, one software company focused on managing processes for plant-to-patient operations. The recent acquisition an irrigation and greenhouse technology company has rounded out MedCana’s portfolio of companies. MedCana’s initial focus is on developing clients and companies in Latin America with an initial focus in Colombia and partnerships with laboratories, research facilities, and hospitals throughout the world.

SAFE HARBOR STATEMENT

This press release contains forward-looking statements that can be identified by terminology such as “believes,” “expects,” “potential,” “plans,” “suggests,” “may,” “should,” “could,” “intends,” or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results implied by such statements. These factors include, but are not limited to, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company’s control. Forward-looking statements speak only as to the date they are made, and we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

Contact:

Jose Gabriel Diaz, CEO

www.medcana.net

info@medcana.co

Contact Details

MedCana

info@medcana.co

Company Website

https://www.medcana.net/

MIAMI, Dec. 07, 2022 (GLOBE NEWSWIRE) — Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a Healthcare Analytics provider with interests in the psychedelic and mental health sectors, today issued a letter to shareholders from its Chief Executive Officer, Ben Kaplan.

Dear Fellow Shareholders

As 2022 draws to a close, many of us will reflect on a year that saw global economic activity experiencing a broad-based and sharper-than-expected slowdown, increased inflation higher than we have seen in several decades, and higher interest rates. Despite these challenges and many others, I am very proud of our Ehave team’s accomplishments in advancing our business plan. Our team executed several vital acquisitions, expanded our research capabilities, and realized many more achievements in our effort to continue to build on our strong foundation.

At the outset, I would like to provide an update on the triangular merger between our publicly traded Mycotopia Therapies (OTC: TPIA) subsidiary, Ei.Ventures, and PSLY.com. The $380 million transaction is structured to close when PSLY.com receives approval for trading on NASDAQ. We are following the procedures for this process as set forth by NASDAQ and the SEC. All parties involved are committed to completing the transaction. This transaction is important to Ehave shareholders because Ehave owns approximately 9,793,754 shares of Mycotopia Therapies. I expect to provide additional updates on this transaction and how it will affect our Ehave shareholders in the near future.

KetaDASH

I want to highlight several significant milestones our Ehave team has achieved in 2022. In February, Ehave purchased 100% of Rejuv IV, a mobile IV therapy provider in the San Francisco Bay Area. Rejuv IV became KetaDASH, a wholly owned subsidiary of Ehave, Inc. KetaDASH provides mobile Ketamine treatments for treatment-resistant depression, anxiety, PTSD, and other conditions, as well as IV infusions with fluids, essential vitamins, minerals, and electrolytes to enhance the health and wellness of its patients. After an initial telemedicine visit, a team of experienced physicians, therapists, and nurses administer every KetaDASH treatment in the patient’s home, office, or mobile location. This innovative service departs from in-clinic intravenous, treatment, or unsupervised telehealth models to an at-home ketamine administration with telehealth and in-person medical supervision.

A typical KetaDASH experience incorporates a prescribing doctor, a nurse for administration and monitoring, and psychotherapists for integration, all from the comfort of the patient’s home. Our KetaDASH team is pioneering efforts in precision medicine through Ehave’s partnership with Entheon Biomedical Corp.’s (CSE: ENBI) (OTCQB: ENTBF) HaluGen Life Sciences division. Our KetaDASH subsidiary is one of the first psychedelic companies to test patients with HaluGen’s expanded psychedelics genetic testing panel. This panel analyzes a series of relevant DNA biomarkers and utilizes pre-screening mental health surveys in order to provide insights into an individual’s risk and potential for adverse reactions with the use of ketamine. Ehave’s KetaDASH subsidiary is fully operational in Sacramento and San Francisco.

KetaDASH Miami

In June, Ehave took delivery of its first mobile KetaDASH unit, a custom high-end medical van utilizing KetaDASH’s software platform. The KetaDASH Mobile Unit was specifically designed to focus on the efficacy of the treatment in a relaxed setting with the patient’s safety and comfort in mind. At the present time, KetaDASH is focusing on health, wellness, and mental health in the Miami area. KetaDASH currently does not offer ketamine treatments in Miami, but plans to start offering them in the first half of 2023.

KetaDASH Miami currently offers IV infusions with fluids, essential vitamins, minerals, and electrolytes to enhance the health and wellness of its patients. These infusions include IV Drip Detox and Hangover Cures, IV Vitamin Therapy for Pain Management, IV Hydration Therapy for Health & Wellness, and IV Therapy for Athletic Advantage and Fitness Recovery. Every infusion is administered by a qualified health care professional to ensure the safety of our patients.

Follow KetaDASH on Instagram at www.instagram.com/ketadash.usa.

MetaHealthU

MetaHealthU provides patients with a way to integrate providers, create troves of usable data for researchers, and clinicians to improve the care our nation’s health system provides to its patients, providing a platform for precision health and giving patients ownership of their data. MetaHealthU focuses on interoperability, population health, and data ownership, and it has created a system that will work by providing patients the opportunity to own their health data.

We reached a milestone of 600 new users on our MetaHealthU platform during the last half of the year. The new users have found tremendous success with the platform and have compiled usable data on specific medical conditions like erectile dysfunction and fatigue. Many of these users have also used our mobile services in KetaDASH Miami.

Our Ehave team developed MetaHealthU as a powerful mobile application platform that empowers individuals to take complete control of their health and their healthcare data. With MetaHealthU, users can securely track all their health data from wearables, Electronic Health Records Systems (EHRs), doctors, and medical labs. The app is available for iOS 11.0 or later and Android. It includes a “digital file cabinet” for medical records. Users can log into their patient portals on various healthcare systems and medical labs and download their medical records in the digital file cabinet. Its features include easy-to-use navigation and search capabilities for users to collect, file, and tag their medical records on a mobile device. More information on MetaHealthU, as well as a free download of the app, can be found at https://apps.apple.com/us/app/metahealthu/id1600512401.

MetaHealthYuru

MetaHealthYuru is a personal mental health monitor that screens for early signs of mental health conditions, such as stress and depression. MetaHealthYuru uses voice analysis to screen for early signs of mental health conditions using a speech-based AI technology. Our MetaHealthYuru platform could potentially predict risk for various types of depression and mood and anxiety-based disorders years before a clinical diagnosis is obtained. This is accomplished by using vocal biomarkers to recognize your real emotional state and mood while tracking your mental health. Our technology can help detect and monitor subtle changes in the mental state by assessing individuals more frequently and objectively than the assessments used today. MetaHealthYuru can track your emotions and mood, analyze your mental state, and suggest potential treatments available for improving your mental well-being.

2023 and Beyond

In 2022 our Ehave team focused its efforts on developing our existing projects. We started the year with a large number and developed suitable metrics to gauge which ones will benefit the most from our resources. Moving forward, we intend to unlock the value created with our Mycotopia Therapies subsidiary and some of the company’s other investments. We also intend to focus our efforts on expanding our KetaDASH and MetaHealthU subsidiaries to propel Ehave into 2023 and beyond.

There is so much more to come.

Sincerely,

Ben Kaplan

Chairman and CEO, Ehave, Inc.

About Ehave, Inc.

Ehave is a leading healthcare services and technology company, focused on progressing psychedelics-to-Therapeutics by engineering novel compounds and new treatment protocols for treating brain health. Together with our network of scientists and mental health professionals, we are on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues, leveraging clinical data to help us achieve optimal patient outcomes. Ehave’s operations span across the entire USA, Canada, Jamaica, and Australia. Additional information on Ehave can be found on the Company’s website at: www.ehave.com.

Forward-Looking Statement Disclaimer

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading “Risk Factors” in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC’s website, http://www.sec.gov.

For Media and Investor Relations, please contact:

David L. Kugelman

(866) 692-6847 Toll Free – U.S. & Canada

(404) 281-8556 Mobile and WhatsApp

Email: [email protected]

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Herzliya, Israel and Calgary, Alberta–(Newsfile Corp. – November 29, 2022) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the “Company” or “Innocan”) a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary IP portfolio, is pleased to report its financial results for the three and nine months ended September 30, 2022.

“We delivered encouraging results in the third quarter, with revenue growth and are confident in our long-term outlook” says Iris Bincovich, CEO of Innocan, “we continue with our strategy to invest in cutting-edge science and innovation while deliver revenues from our consumer wellness activities.”

Additional information concerning Innocan’s consolidated financial statements and related management’s discussion and analysis for the three and nine months ended September 30, 2022 can be found at www.sedar.com.

Financial highlights for the third quarter 2022

• Revenue – A consistent increase in revenue has been remarked over the last 12 months was USD 1.424M for the quarter ended September 30, 2022, representing a 700% increase from the $180 thousand in third quarter in the prior year. The consistent increase in revenues indicates continued growth and expansion of the Company’s activities.
• Gross Profit – was USD 511 thousand for the quarter ended September 30, 2022, representing a 360% increase from the USD 180 thousand in third quarter in the prior year. The increase in operating profit is another indicator of the growth of the Company’s activity.
• Net loss – was USD 2.7M for the quarter ended September 30, 2022, representing a 71% decrease from the USD 9.4M thousand in third quarter in the prior year. This is mainly because of changes in fair value of warrants outstanding during the period of Q3-22 in compared to the corresponding quarter.
• Working capital – was USD 7.7M for the quarter ended September 30, 2022, representing a 17% increase from the USD 6.6M in third quarter in the prior year.
• Cash balance – was USD 6.4M for the quarter ended September 30, 2022, representing a 10% increase from the USD 5.8M in third quarter in the prior year.

About Innocan

Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD- loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. (ii) CLX CBD-loaded exosomes platform that may hold the potential to provide a highly synergistic effect of regenerating and anti- inflammatory properties targeting the Central Nervous System (CNS). In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO

15162104025+

+972-54-3012842

+442037699377
[email protected]

Dr. Eva Reuter

Investment Relation- Germany

+46-69-1532-5857

[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company’s products, requisite regulatory approvals and the timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

LOS ANGELES and DESERT HOT SPRINGS, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) — via InvestorWire — Grapefruit USA, Inc. (OTCQB: GPFT) (“Grapefruit” or the “Company”), an innovative California-based cannabiotech company, is updating its recent announcement of the proposed acquisition of Diagnostic Lab Corporation of Englewood Cliffs, New Jersey (“DLC”), a diversified food and agriculture safety company, and the recapitalization of the Company. On Aug. 18, 2022, the Company reported that it was “finalizing its due diligence on DLC, and is in the final stages of negotiating the terms of its anticipated financing and structuring the transaction documents, all of which it expects to complete in the next several weeks.” The Company is reporting today that despite current general market and economic conditions, the anticipated transaction and financing process is active and continuing, with all terms and conditions of financing and structure expected within the next 30 days.

Bradley J. Yourist, Grapefruit’s CEO and co-founder, commented, “We are providing this update at this time to inform our many loyal shareholders that the Company is making significant progress with respect to the DLC acquisition, despite the challenging current macroeconomic environment and its influence on capital markets. Despite these potential distractions, Grapefruit’s management, staff and outside professionals continue to work very efficiently together to ensure a successful acquisition of DLC as the next event in the Company’s evolution to a wellness-driven, medical science-based, canna-focused biotech company.”

To purchase Grapefruit’s groundbreaking patented Hourglass CBD delivery topical cream outside of Canada, please visit: https://hourglassonlinestore.com/

To learn more about Grapefruit’s new sustained-release patented Hourglass THC + Cannabinoid topical cream, please watch this promotional video: https://www.youtube.com/watch?v=6cU9MJMgH1w&feature=youtu.be and visit our website at: https://grapefruitblvd.com/hourglass/

For investor information, please visit Grapefruit’s website at:
https://grapefruitblvd.com/investor-relations/

Follow Grapefruit on Facebook, Instagram, LinkedIn and Twitter:
Facebook | Instagram | LinkedIn | Twitter

About Grapefruit

Grapefruit’s corporate headquarters is in Westwood, Los Angeles, California. Grapefruit holds California permits and licenses to both manufacture and distribute cannabis products in the Golden State. Grapefruit’s extraction laboratory and manufacturing and distribution facilities are located in the industry-recognized Coachillin’ Industrial Cultivation and Ancillary Canna-Business Park in Desert Hot Springs, located on the extension of North Canyon Road, approximately 14 miles north of downtown Palm Springs. To obtain further information on Grapefruit and its operations, please visit the Company’s website at https://grapefruitblvd.com/.

Safe Harbor Statement

Grapefruit cautions that any statement included in this press release that is not a description of historical facts is a forward-looking statement. Many of these forward-looking statements contain the words “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect” and similar expressions. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties inherent in Grapefruit’s business, including, without limitation: the Company may not ever obtain additional funds necessary to support its business development and growth plans; and the Company may not ever achieve the market success to reach or sustain a profitable business. In addition, there are risks and uncertainties related to economic recession or terrorist actions, competition from much larger cannabis companies, unexpected costs and delays, potential product liability claims and many other factors. More detailed information about Grapefruit and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, its Quarterly Report on Form 10-Q for the period ended Sept. 30, 2022, and its Registration Statement on Form S-1/A. Such documents may be read free of charge on the SEC’s website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Grapefruit undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

Investor Relations Contact:
Bradley Yourist
[email protected]
18776 Blue Dream Crossing, Unit LL1 53-07
Desert Hot Springs, California 92240
(760) 205-1382
https://grapefruitblvd.com/

Please be aware that our social media accounts can be used from time to time for additional material events. They can be found here:

Grapefruit USA:
Facebook: https://www.facebook.com/Grapefruit-Boulevard-2304698596251925/
Instagram: https://www.instagram.com/grapefruit_usa/
Twitter: https://twitter.com/grapefruitusa
LinkedIn: https://www.linkedin.com/company/grapefruit-boulevard/
Weedmaps: https://weedmaps.com/brands/grapefruit

Corporate Communications:
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

– Eighth Consecutive Quarter of Year-Over-Year Revenue Growth –

– Initial Mary Jones Cannabis Product Launch Beats Internal Expectations and Generates Enthusiastic Consumer Feedback and Demand –

SEATTLE, Aug. 04, 2022 (GLOBE NEWSWIRE) — Jones Soda Co. (CSE: JSDA, OTCQB: JSDA) (“Jones Soda” or the “Company”), the original craft soda known for its unconventional flavors and user-submitted photo labels, announced its financial results for the second quarter ended June 30, 2022.

Second Quarter 2022 Financial Highlights vs. Year-Ago Quarter

• Revenue increased 35% to $6.0 million compared to $4.5 million.
• Gross profit as a percentage of revenue was 28.0% compared to 31.3%.
• Net loss was $1.4 million, or $(0.02) per share, compared to a net income of $0.3 million, or $0.00 per share.
• Adjusted EBITDA¹ was $(1.1) million compared to $0.4 million. Adjusted EBITDA included approximately $1.2 million in expenses related to the development and roll-out of the Company’s new cannabis products during the second quarter of 2022.

Management Commentary

“We continued to capitalize on the strong momentum we started the year with, resulting in our eighth consecutive quarter of year-over-year revenue growth,” said Mark Murray, President and CEO of Jones Soda. “Our core bottled soda business was the main driver behind our solid sales results, where we saw continued strength in our retail and alternative channels throughout the quarter. While we experienced modest year-over-year margin compression mostly due to a combination of product mix and inflationary pressures, we remained in-line with our internal expectations for this quarter. I am very proud of our team’s ability to adapt under a dynamic macro-environment and continue to execute on our three-year strategic turnaround plan.

“Our strong sales performance continues to validate the three-year plan we implemented in late 2020. We continue to improve the health of our business by supporting and growing our core retail presence, while also opening new points of distribution in alternative channels. Through deeper engagement with existing relationships and several additional distribution agreements in these new channels, our customer base is larger, more diversified, and we believe more sustainable. We will continue to support this progress with a strong focus on improving our product mix and ensuring we have the right products on customers’ shelves at the right times. In addition, our marketing team continues to drive velocity and deliver high returns on our marketing investments. With a special release flavor set to debut in the coming months and our AR labels driving higher engagement rates within the Jones Soda community, we believe our sales and marketing strategies continue to define the Company and strategically position us for long-term, profitable growth across all our channels.

“I am also pleased to report that we are receiving overwhelmingly positive feedback from our initial Mary Jones cannabis launch. Having secured strong manufacturing and distribution partnerships during the second quarter of 2022, we believe we are in an excellent position to fulfill the anticipated high demand we have already begun generating. Our attention-grabbing launch sets the stage for more exciting products scheduled to be released in the coming months. We believe our full cannabis product portfolio featuring our 100mg beverage and innovative format edibles will help improve our sales margins, while satisfying consumer and retail demand for products with higher potency, portability and versatility. We intend to continue to establish our position within the cannabis space by expanding into new markets and further developing the Mary Jones brand into a household name.

“With the strong foundation that we have built in our core soda business and the foothold we hope to secure in the cannabis market, we expect to continue executing on our turnaround strategy for the remainder of the year. Although the macro-economy can be unpredictable and we are keeping a close eye on consumer demand in an inflationary environment, we remain committed to executing upon initiatives within our control. We will continue to support our growth in alternative channels, develop new and innovative flavors that engage with the Jones Soda community, and capitalize on the momentum we are generating with the launch of Mary Jones. As we work to further establish Jones Soda as a leading craft soda and cannabis company, the expansion of the Jones brand and the realization of value back to our shareholders remains our highest priority.”

Second Quarter 2022 Financial Results

Revenue in the second quarter of 2022 increased 35% to $6.0 million compared to $4.5 million in the prior year period. The revenue growth was primarily attributable to sustained growth in the Company’s retail and alternative sales channels for its core bottled business.

Gross profit as a percentage of revenue was 28.0% for the second quarter of 2022 compared to 31.3% in the year-ago period. The decrease in gross profit margin was primarily driven by the impacts of inflation, mostly driven by increased material and freight costs, and the overall impacts of product mix for the quarter.

Net loss for the second quarter of 2022 was $1.4 million, or $(0.02) per share, compared to a net income of $0.3 million, or $0.00 per share, in the second quarter of 2021. The increase in net loss was primarily attributable to the $1.2 million of operating expenses and development costs related to the Company’s strategic entry into the cannabis sector in the current quarter, combined with a one-time $334,500 benefit recorded in the prior year period in connection with the forgiveness of a loan previously granted to the Company under the Payment Protection Program (PPP).

Adjusted EBITDA¹ in the second quarter of 2022 was $(1.1) million compared to $0.4 million the prior year period. The decline was primarily driven by the aforementioned increase in operating expenses associated with the Company’s strategic entry into the cannabis sector and the aforementioned one-time benefit in the prior year period associated with the forgiveness of a loan previously granted to the Company under the PPP.

At June 30, 2022, cash and cash equivalents totaled $9.3 million compared to $4.7 million at December 31, 2021. As of June 30, 2022, all convertible debentures have been converted and the Company does not have any substantial debt.

_______________
¹ Adjusted EBITDA is defined as net income (loss) from operations before interest expense, interest income, taxes, depreciation, amortization and stock-based compensation and is a non-GAAP measure (reconciliation provided below).

Conference Call

Jones Soda will hold a conference call today at 4:30 p.m. Eastern time to discuss its results for the second quarter ended June 30, 2022.

Date: Thursday, August 4, 2022
Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Toll-free dial-in number: 1-877-545-0523
International dial-in number: 1-973-528-0016
Conference ID: 429299

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Gateway Group at 1-949-574-3860.

The conference call will be broadcast live and available for replay here and via the investor relations section of the Company’s website at www.jonessoda.com.

A replay of the conference call will be available after 7:30 p.m. Eastern time on the same day through August 18, 2022.

Toll-free replay number: 1-877-481-4010
International replay number: 1-919-882-2331
Replay ID: 46142

Presentation of Non-GAAP Information

This press release contains disclosure of the Company’s Adjusted EBITDA, which is not a United States Generally Accepted Accounting Principle (“GAAP”) financial measure. The difference between Adjusted EBITDA (a non-GAAP measure) and Net Loss (the most comparable GAAP financial measure) is the exclusion of interest expense and income, income tax expense, depreciation and amortization expense and stock-based compensation. We have included a reconciliation of Adjusted EBITDA to Net Loss under “Non-GAAP Reconciliation” at the end of this press release. This non-GAAP measure should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for or superior to the Company’s GAAP financial measures. Adjusted EBITDA has certain limitations in that it does not take into account the impact of certain expenses to our consolidated statements of operations. In addition, because Adjusted EBITDA may not be calculated identically by all companies, the presentation here may not be comparable to other similarly titled measures of other companies. The Company believe that Adjusted EBITDA provides useful information to investors about the Company’s results attributable to operations, in particular by eliminating the impact of non-cash charges related to stock-based compensation, amortization and depreciation that is consistent with the manner in which we evaluate the Company’s performance. These adjustments to the Company’s GAAP results are made with the intent of providing a more complete understanding of the Company’s underlying operational results and to provide supplemental information regarding our current ability to generate cash flow. This non-GAAP financial measure is not intended to be considered in isolation or as a replacement for, or superior to Net Loss as an indicator of the Company’s operating performance, or cash flow, as a measure of its liquidity. Adjusted EBITDA should be reviewed in conjunction with Net Loss as calculated in accordance with GAAP.

About Jones Soda Co.

Jones Soda Co.® (CSE: JSDA, OTCQB: JSDA) is a leading craft soda manufacturer with a growing line of cannabis products. The Company markets and distributes premium craft sodas under the Jones® Soda and Lemoncocco® brands, and a variety of cannabis products under the Mary Jones brand. Jones’ mainstream soda line is sold across North America in glass bottles, cans and on fountain through traditional beverage outlets, restaurants and alternative accounts. The Company is headquartered in Seattle, Washington. For more information, visit www.jonessoda.com, www.myjones.com, www.drinklemoncocco.com or www.MaryJonesCannabis.com.

Forward-Looking Statements Disclosure

Certain statements in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all passages containing words such as “will,” “aims,” “anticipates,” “becoming,” “believes,” “continue,” “estimates,” “expects,” “future,” “intends,” “plans,” “predicts,” “projects,” “targets,” or “upcoming.” Forward-looking statements also include any other passages that are primarily relevant to expected future events or that can only be evaluated by events that will occur in the future. Forward-looking statements are based on the opinions and estimates of management at the time the statements are made and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated or implied in the forward-looking statements. Factors that could affect the Company’s actual results, including its financial condition and results of operations, include, among others: its ability to successfully execute on its growth strategies and operating plans for the future; the Company’s ability to continue to effectively utilize the proceeds from its recent financings, including its recent debenture financings, and from the Company’s recently completed plan of arrangement; the Company’s ability to execute its plans to develop and market THC/CBD-infused and/or cannabis-infused beverages and edibles, and comply with the laws and regulations governing cannabis, hemp or related products, and the timing and costs of the development of these new product lines; the Company’s ability to manage operating expenses and generate sufficient cash flow from operations; the Company’s ability to create and maintain brand name recognition and acceptance of its products; the Company’s ability to adapt and execute its marketing strategies, especially in light of the restrictions caused by the COVID-19 pandemic; the Company’s ability to compete successfully against much larger, well-funded, established companies currently operating in the beverage industry generally and in the craft beverage segment specifically; the Company’s ability to respond to changes in the consumer beverage marketplace, including potential reduced consumer demand due to health concerns (including obesity) and legislative initiatives against sweetened beverages (including the imposition of taxes); its ability to develop and launch new products and to maintain brand image and product quality; the Company’s ability to maintain and expand distribution arrangements with distributors, independent accounts, retailers or national retail accounts; its ability to manage inventory levels and maintain relationships with manufacturers of its products; its ability to maintain a consistent and cost-effective supply of raw materials and flavors and manage the impact of the COVID-19 pandemic and other factors on its supply chain; its ability to attract, retain and motivate key personnel; its ability to protect its intellectual property; the impact of future litigation and the Company’s ability to comply with applicable regulations; its ability to maintain an effective information technology infrastructure, fluctuations in freight and fuel costs; the impact of currency rate fluctuations; its ability to access the capital markets for any future equity financing and to manage the impact that the COVID-19 pandemic may have on the Company’s ability to access capital; the Company’s ability to maintain disclosure controls and procedures and internal control over financial reporting; dilutive and other adverse effects from future potential securities issuances; and any actual or perceived limitations by being traded on the OTCQB Marketplace in the United States and the Canadian Securities Exchange in Canada. More information about factors that potentially could affect the Company’s operations or financial results is included in its most recent annual report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission (“SEC”) on March 14, 2022 and in the other reports filed with the SEC since that date. Readers are cautioned not to place undue reliance upon these forward-looking statements that speak only as to the date of this release. Except as required by law, the Company undertakes no obligation to update any forward-looking or other statements in this press release, whether as a result of new information, future events or otherwise.

Company Contact:

Mark Murray
President and CEO
1-206-624-3357

Investor Relations Contact

Cody Cree
Gateway Group, Inc.
1-949-574-3860
[email protected]

JONES SODA CO.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share data)

JONES SODA CO.
CONDENSED CONSOLIDATED BALANCE SHEETS
UNAUDITED

JONES SODA CO.
NON-GAAP RECONCILIATION
(Unaudited, in thousands)

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Toronto, Ontario–(Newsfile Corp. – June 14, 2022) – Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K70) (“Silo Wellness” or the “Company“), a leading global psychedelics company, announces a request for expressions of interests from Oregon property owners who may be considering participation in the regulatory regime under Oregon Ballot Measure 109. “With Silo Wellness as the only publicly traded psychedelic company with legal psychedelic retreat experience and a strong connection to Oregon, we believe we are well positioned to collaborate with other Oregonians interested in participating in this burgeoning market,” stated Silo Wellness founder and Oregon lawyer Mike Arnold.

“Over the past months we have been touring properties with owners and realtors and have really turned up our search for properties that may be suitable for Oregon psilocybin as we await the final rules from the Oregon Health Authority,” Mr. Arnold continued. “However, I also know that there are many property owners who may believe they are sitting on an ideal property for a facility with no interest in selling, but they may not have the legal expertise, network, or capital to make it happen. It is our goal to leverage our platform to help empower Oregonians who may each have a piece of the puzzle – facilitation experience, business experience, property, capital, or a passion for the medicine – and bring them together to help make this industry by Oregonians for Oregonians.”

Parties who may be interested in entering the Oregon psilocybin industry are encouraged to contact Silo Wellness at [email protected].

Silo Wellness Share Consolidation

The Company is also pleased to announce that its Shareholders at its recent annual meeting have authorized the implementation of a consolidation (the “Consolidation”) of the Company’s common shares (the “Shares”) on the basis of one (1) post-Consolidation Share for every twenty (20) pre-Consolidation Shares, which will become effective on June 20, 2022 (the “Effective Date”). Neither the Company’s name, nor its trading symbols, will change as a result of the Consolidation. The Company previously announced on April 14, 2022, of its intent to commence with a share consolidation plan as a condition precedent for the Company’s CAD$5,950,000 financing commitment.

The Company currently has 85,364,744 Shares issued and outstanding and 70,234,824 reserved for issuance. Following the Consolidation, there will be approximately 4,268,237 Shares issued and outstanding and 3,806,116 reserved for issuance. No fractional Shares will be issued, and any fraction of a Share will be rounded down to the nearest whole number of Shares. The Shares will trade on a post-Consolidation basis under the new CUSIP #827124207 and ISIN #CA8271242072. The Shares are expected to begin trading on a post-Consolidation basis on the Canadian Securities Exchange when markets open on the Effective Date.

The exercise or conversion price and the number of Shares issuable under any of the Company’s outstanding convertible securities will be proportionately adjusted upon the effectiveness of the Consolidation.

Shareholders of record as of the Effective Date will receive a letter of transmittal providing instructions for the exchange of their Shares as soon as practicable following the Effective Date. However, shareholders who hold their common shares through a securities broker, dealer, bank or other financial institution will not be required to take any action with respect to the Consolidation and should contact that intermediary for their post-Consolidation positions.

Further details on the Consolidation are contained in the management information circular of the Company previously filed and available under the Company’s profile on SEDAR at www.sedar.com.

ABOUT SILO WELLNESS

Silo Wellness is a growth-oriented holding company focused on functional mushroom and psychedelic opportunities that benefit from a unified ecosystem and exceptional leadership. Founded in 2018 and headquartered in Toronto, Silo Wellness has a presence in both Jamaica and Oregon. Silo Wellness is a publicly traded company on the Canadian (CSE: SILO) and Frankfurt (FSE: CK70) exchanges and trading on the OTCQB Venture Market (OTCQB: SILFF). Silo Wellness offers a diverse and growing portfolio, including psychedelic retreats in Jamaica and Oregon, metered-dosing intellectual property, and the Bob Marley line of functional mushroom products available at www.MarleyOne.com

For more information about Silo Wellness, please visit www.silowellness.com.

Silo Wellness Company Contact:

Mike Arnold, President
541-900-5871
[email protected]

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION: This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates, and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking information may relate to anticipated events or results including, but not limited to the anticipated effective date of the Share Consolidation and the Company’s future business plans. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, regulatory, political and social uncertainties and the potential impact of COVID-19. Such risks and uncertainties include, among others, the risk factors included in Silo Wellness’s continuous disclosure documents available on www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Readers should not place undue reliance on the forward-looking statements and information contained in this news release. Silo Wellness assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Toronto, Ontario and Los Angeles, California–(Newsfile Corp. – April 25, 2022) – The Tinley Beverage Company Inc. (CSE: TNY) (OTCQX: TNYBF) (“Tinley’s” or the “Company”) is pleased to announce that the launch of its Tinleys 27 Smooth Coconut elixir is continuing to roll out in Ontario. The Company is also pleased to announce that it has received an advance in the aggregate amount of US$612,250 (the “Advance”) from Richard Gillis, President and Chief Operating Officer of Tinley’s USA, and member of Tinley’s Office of the CEO.

Tinley’s Ontario Brand Launch Update

The Company is working with its sales agents, Northern Elements, to introduce Tinleys ’27 Smooth Coconut elixir to an increasing number of dispensaries in key Ontario regional markets since the product’s listing went live earlier this month. To help accelerate retail and consumer uptake, non-infused versions of the product are being offered in store to buyers and are also being made available to dispensaries for consumer sampling events to illustrate the easy sip, mix, and share possibilities of the Tinleys ’27 Caribbean-inspired elixir. In addition, retail point-of-purchase materials are now available, including counter cards with recipe booklets promoting five use occasions through easy-to-mix at home mocktail recipes.

The product continues to be available online via the Ontario Cannabis Store (the “OCS”) website. The Company understands that the OCS reallocates inventory from its warehoused stock in response to online demand, and consumers seeking to order from the OCS website may see the product shown as out of stock, and then find the product available to order hours later or the following day. The Company further understands that the OCS online internal replenishment cycle is expected to accelerate throughout the first 30-60 days of listing. As previously announced, Tinleys Classics Mystic Dove Paloma-inspired ready-to-drink mocktail is expected to be available to Ontario dispensaries and consumers in May.

Dispensary Counter Card and Easy Recipe Booklets for Tinleys ’27 Smooth Coconut, Now in Ontario Distribution, and Counter Card for Tinleys Classics Mystic Dove, for Expected Distribution in May 2022 (concepts shown).

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/8257/121530_401647b9c4573883_001full.jpg

The Advance

The Advance will be evidenced by a secured, convertible promissory note, the terms and conditions of which are to be determined by the Company and Richard Gillis at a forthcoming date. The proceeds of the Advance will be used for Tinley’s working capital and for general corporate purposes.

The Advance is subject to all necessary approvals, including final approval from the Canadian Securities Exchange.

Regulatory Matters

The Advance is considered a “related party transaction” within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The Company relied on exemptions from the formal valuation and minority approval requirements in sections 5.5(b) and 5.7(1)(a) of MI 61-101 in respect of the Advance. Further details will be provided in the Company’s material change report to be filed on SEDAR. The Company did not file a material change report in respect of the related party transaction less than 21 days prior to the closing of the transaction, which the Company deems reasonable in the circumstances so as to be able to avail itself of the proceeds of the Advance in an expeditious manner.

Other Corporate Updates: Previously Announced Acquisition Transaction

Tinley’s is pleased to announce that the Company and Lakewood Libations, Inc. (“Lakewood”) have received approval by the City of Long Beach, California for the previously announced agreements for Tinley’s to purchase one hundred percent (100%) of the shares of Lakewood from Richard Gillis for a nominal fee, (the “Acquisition Transaction”). The Company and Lakewood have now submitted the final applications for the change of control of Lakewood to the State of California. The State’s approval, barring unforeseen delays, may be expected on or about the end of Q2 2022. State approval will be the final step in the previously announced change of control of Lakewood and the closing of the Acquisition Transaction.

About The Tinley Beverage Company and Beckett’s Tonics

The Tinley Beverage Company Inc. (CSE: TNY) (OTCQX: TNYBF) develops and has licensed the production through its Long Beach, CA state-licensed manufacturing facility of terpene and cannabis-infused non-alcoholic Tinley’s ’27 and Tinley’s Tonics products which are distributed to licensed dispensaries and home delivery channels in California. Expansion of these products, adapted for manufacturing and sale in Canada, is currently underway under the Tinleys ’27 and Tinleys Classics brands. The Beckett’s Classics and Beckett’s ’27 lines of non-alcoholic, terpene-infused non-cannabis versions of these formulations are available in select mainstream food, beverage, and specialty retailers, as well as online, in the United States as well as in select grocery and specialty stores in Canada. Tinley’s facility in Long Beach California contains some of the state’s most versatile and technologically advanced cannabis-licensed beverage manufacturing equipment and provides manufacturing and first-mile distribution services under one roof for third-party brands in addition to Company-owned brands. Please visit www.drinktinley.com, and www.drinkbecketts.com Twitter and Instagram (@drinktinleys and @drinkbecketts) for recipes, product information and home delivery options.

Forward-Looking Statements

This news release contains forward-looking statements and information (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities laws. Forward-looking statements are statements and information that are not historical facts but instead include financial projections and estimates, statements regarding plans, goals, objectives and intentions, statements regarding the Company’s expectations with respect to its future business and operations, the closing of the previously announced Lakewood Acquisition, the timing of the Company’s manufacturing capability enhancements and production runs, revenue growth, management’s expectations regarding growth, the expected benefits from facility and equipment upgrades, expected benefits from first-mile distribution services enabled by the on-site distribution licence, the timing of the manufacturing, distribution and sale of Tinley’s infused products in Canada, the timing of the production of new batches of client products at Tinley’s Long Beach Facility and phrases containing words such as “ongoing”, “estimates”, “expects”, or the negative thereof or any other variations thereon or comparable terminology referring to future events or results, or that events or conditions “will”, “may”, “could”, or “should” occur or be achieved, or comparable terminology referring to future events or results. Factors that could cause actual results to differ materially from any forward-looking statement include, but are not limited to, delays in obtaining or failures to obtain required governmental, environmental, or other project approvals, political risks, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, changes in exchange rates, fluctuations in commodity prices and delays in the development of projects. Forward-looking statements are subject to significant risks and uncertainties, and other factors that could cause actual results to differ materially from expected results. Readers should not place undue reliance on forward-looking statements. These forward-looking statements are made as of the date hereof and the Company assumes no responsibility to update them or revise them to reflect new events or circumstances other than as required by law. Products, formulations, and timelines outlined herein are subject to change at any time.

For further information, please contact:

The Tinley Beverage Company Inc.
Ted Zittell
(310) 507-9146
[email protected]
(CSE: TNY) (OTCQX: TNYBF)

Twitter: @drinktinleys and @drinkbecketts
Instagram: @drinktinleys and @drinkbecketts
www.drinktinley.com

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Company poised for rapid expansion in 2022 after highly successful 2021, in which it secured commercial deployments across three continents, US FDA registration and multiple awards for innovation in AI

VANCOUVER, BC, Jan. 11, 2022 /CNW/ – Cognetivity Neurosciences Ltd. (the “Company” or “Cognetivity”) (CSE: CGN) (OTCQB: CGNSF) (FWB: 1UB) has provided an update on the significant progress it made during 2021, setting the company up for rapid growth in 2022 and beyond.

2021 saw Cognetivity reach important commercial agreements in three continents and across a variety of use cases. The company extended its track record of successful implementation in the UK’s National Health Service (NHS), achieving deployments in two of the country’s largest and most prestigious mental health trusts, South London and Maudsley (SLaM) NHS Foundation Trust and Birmingham and Solihull Mental Health NHS Foundation Trust (BSMHFT). The innovative Birmingham deployment covered both primary and secondary care and was facilitated by Cognetivity’s ongoing partnership with the world-leading data and interoperability platform provider InterSystems.

Outside the UK, Cognetivity launched in the Middle East and confirmed its first deployment in the region within weeks, at the state-of-the-art Clemenceau Medical Center in Dubai, UAE. Cognetivity also took its crucial first steps into the North American healthcare market, striking a deal with the next-generation health and wellness company Ketamine One that saw the Integrated Cognitive Assessment (ICA) rolled out in clinics throughout the US and Canada.

The Ketamine One agreement, alongside deals with the Dutch telehealth company Luscii and the UK-based residential care provider Loveday, demonstrated that the ICA has very broad applicability extending beyond its core use of enhancing dementia detection and diagnosis.

Beyond these commercial deals, Cognetivity also received formal recognition of its ground-breaking work throughout 2021 in the form of numerous awards and program invitations. In February, it was awarded a place on the ‘Scaleup Programme’ run by Innovate UK, the UK Government’s innovation agency, having been judged as capable of achieving at least 50% annual growth. In September, it was selected to join the prestigious Health Batch 13 program run by the Silicon Valley-based open innovation platform Plug and Play, which has previously backed household names such as Dropbox and PayPal. Finally, to round off the year, the company won two prizes in the UK celebrating its innovation in artificial intelligence, at the 2021 Health Tech Awards and Cloud Excellence Awards.

In conjunction with these high-profile achievements, Cognetivity spent the year strengthening the underlying foundations necessary for the company to achieve further global success in 2022 and beyond. On the regulatory front, it completed the registration of its technology with the US Food and Drug Administration (FDA), allowing the ICA to be marketed as a medical device for commercial distribution throughout the US, which has the largest national healthcare market in the world.

The company also filed a key new patent covering the use of an AI-based system to estimate levels of core biomarkers of neurodegeneration in the brain. The patent will enable the ICA platform to be licensed for much-needed biomarker assessment in the pharmaceutical and healthcare industries, particularly as Aduhelm (aducanumab) and other disease-modifying Alzheimer’s drugs revolutionise the field of dementia treatment over the next few years.

Moreover, the company continued to build on the scientific evidence validating the use of the ICA in diverse clinical settings. In July, it published a research paper in the peer-reviewed journal Frontiers in Psychiatry, which provided further evidence of the ICA’s sensitivity to early-stage Alzheimer’s Disease, freedom from cultural or educational bias and suitability for remote patient monitoring. The company also presented significant new results at two of the largest Alzheimer’s conferences in the world, the Alzheimer’s Association International Conference (AAIC) in July and the Clinical Trials on Alzheimer’s Disease (CTAD) Conference in November.

Cognetivity remains committed to the importance of robust evidence in driving changes in healthcare. At the start of last year, it announced the expansion of its UK government-funded study to include research on the use of the ICA to conduct Covid-safe remote cognitive assessments. In December, meanwhile, it entered into a collaborative partnership with Ketamine One, alongside the ongoing commercial agreement between the two companies, to study and develop assessments for depression and post-traumatic stress disorder (PTSD).

Finally, Cognetivity used 2021 to bolster its advisory board with a series of impressive appointments. Four individuals with a wealth of experience spanning academia, healthcare policy, NHS management and industry joined the Cognetivity team: Ed Smith, former Chairman of NHS Improvement; Dr Carol Routledge, former Director of Research at Alzheimer’s Research UK; Lord O’Shaughnessy, former UK health minister; and the internationally-renowned geriatric psychiatrist Professor Dag Aarsland.

Commenting on the overview of Cognetivity’s success in 2021, the company’s co-founder and CEO, Dr Sina Habibi, said, “We’re delighted at everything that we’ve managed to achieve over the past year. The pandemic has continued to make all aspects of our work challenging – from our commercial efforts to our research and regulatory goals – and yet across the board I’m thoroughly pleased and proud of what we have accomplished. It’s no surprise that we’ve attracted more and more media attention, featuring in The Economist, WIRED magazine, the BBC and The Times last year, among many others.”

“Of course, we have no intention of slowing down,” Dr Habibi continued. “Everything we have done in 2021 has been with an eye to the future. We are poised for rapid expansion throughout 2022 in the UK, the Middle East and the US, as we continue to pursue our goal of transforming dementia care and improving health outcomes for millions of people across the entire world.”

About Cognetivity Neurosciences Ltd.

Cognetivity is a technology company that has created a cognitive testing platform for use in medical, commercial and consumer environments. Cognetivity’s ICA uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of cognitive impairment by testing the performance of large areas of the brain. The ICA is currently available for clinical use in the USA, UK and Europe, with regulatory approval for other regions planned for 2022.

For more information, please visit: www.cognetivity.com

ON BEHALF OF THE BOARD
“Sina Habibi”
Sina Habibi
Chief Executive Officer and Director

FORWARD-LOOKING STATEMENTS:

Certain statements included in this news release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “assume” “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This news release contains forward looking statements. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Such statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Readers should not place undue reliance on the Company’s forward-looking statements.

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Cognetivity Neurosciences Ltd

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Toronto, Ontario–(Newsfile Corp. – January 6, 2022) – Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K70) (“Silo Wellness” or the “Company“), a leading global psychedelics company, is pleased to announce that the Company’s Chief Executive Officer, Douglas K. Gordon, has been appointed as a director of the company. Mr. Gordon has led the company since 2020, through its pre-listing fundraising and into the public markets in March 2021, focusing on psychedelic retreats in Jamaica and the Marley One line of functional mushroom products. Mr. Gordon is the founder of CanEx Jamaica, the premier cannabis business conference and expo in the Caribbean. He has over 30 years of experience spanning finance, media, sales and marketing. Mr. Gordon has forged a vast global network with particular attention to developing business opportunities in the Caribbean and LATAM. Mr. Gordon has developed government and distribution relations in Jamaica as an experienced operator of a health and wellness distribution business and psychedelic retreats.

Mr. Gordon was the architect behind the launch of the Marley One line of mushroom products in collaboration with the Bob Marley estate. The initial Marley One product offering was launched on the e-commerce store, found at www.MarleyOne.com, and included a range of functional mushroom tinctures with unique blends highlighting the brand’s connection to Jamaica. The tinctures include species such as cordyceps, lion’s mane, chaga, reishi and turkey tail that offer a range of unique health and wellness benefits, from immunity and gut health to cognitive function and sleep enhancement. Additionally, the Company was approved for listing on Amazon on August 9, 2021. The approval permits the Company to make its five skus available for sale on the Amazon e-commerce website. Expected sales will depend on the sales and marketing plan, which will include marketing expenditure for targeted advertisements on Amazon to boost the profile of the Company’s products on the website. This is an addition to and not in lieu of the Company’s other sales platforms and opportunities, including the Company’s flagship e-store. The Company has also been working with other manufacturers and sampling new functional mushroom food products in various product categories. The Company is also in negotiations with two different beverage manufacturers in two different product categories, which may or may not be successfully consummated. One has advanced to the R&D stage with functional mushroom compounds provided by the Company to the potential partner, and the Company received the first iteration of beverage samples on or about December 3, 2021.

Silo Wellness also announces that Mo Yang has resigned from the board of directors of the Company to pursue other opportunities. Silo Wellness would like to thank Mr. Yang for his service to the Company since 2020. His financial expertise and operational support were critical to the Company’s early milestones.

Other Corporate Updates

On August 11, 2021, the Company entered into a loan agreement with an arm’s length party for principal amount of $250,000 bearing interest at an annual rate of 6%. On August 12, 2021, the Company repaid $144,000 of the loan principal by issuing 2,500,000 common shares of the Company valued at CAD$0.072 a share (CAD$180,000 or $144,000). On September 16, 2021, the Company repaid $66,360 of the loan principal by issuing 1,500,000 common shares of the Company valued at CAD$0.056 a share (CAD$84,000 or $66,360). On December 27, 2021, the Company agreed to issue 1,062,612 common shares of the Company valued at CAD$0.05 for settling the unpaid total principal and interest of $40,911. Completion of the Shares for Debt is subject to compliance with applicable regulations, including policies of the CSE.

On December 27, 2021, the Company agreed to issue 600,000 common shares valued at CAD$30,000 to settle a debt owed to an arm’s length service provider, subject to CSE approval. On December 27, 2021, the Company also granted 1,000,000 common shares purchase options to 4 directors and the CEO of the Company, each option entitles the holder to purchase one common share of the Company at CAD$0.05 until five years from the grant date. The options are subject to a four-month hold period, and vest in equal quarterly tranches over a year.

ABOUT SILO WELLNESS

Silo Wellness is a growth-oriented holding company focused on functional mushroom and psychedelic opportunities that benefit from a unified ecosystem and exceptional leadership. Founded in 2018 and headquartered in Toronto, Silo Wellness has operations in Jamaica and Oregon. Silo Wellness is a publicly-traded company on the Canadian (CSE: SILO) and Frankfurt (FSE: 3K70) exchanges and trading on the OTCQB Venture Market (OTCQB: SILFF).

Silo Wellness offers a diverse and growing portfolio of functional mushroom products, psychedelic wellness retreats in Jamaica and Oregon, cultivation of psychedelic mushrooms and truffles in Jamaica, development of a brick-and-mortar smart shop in Jamaica, and intellectual property, focused initially on the commercialization of its metered-dosing psilocybin nasal spray.

In March 2021, Silo Wellness announced a multi-year licensing agreement with the family of legendary musician Bob Marley for the exclusive worldwide rights to brand, market and sell a distinct product line of functional and psychedelic mushrooms. The Marley One line of functional mushrooms is available at www.MarleyOne.com.

For more information about Silo Wellness, please visit www.silowellness.com.

For further information, please contact:

Silo Wellness Investor Relations and Media Relations:

Mike Arnold, President
541-900-5871
[email protected]

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION: This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates, and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to: the Shares for Debt and the business plans of Silo Wellness. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, regulatory, political and social uncertainties and the potential impact of COVID-19. Such risks and uncertainties include, among others, the risk factors included in Silo Wellness’s continuous disclosure documents available on www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Readers should not place undue reliance on the forward-looking statements and information contained in this news release. Silo Wellness assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.